DVT Treatment Guideline Recommendations

Initial Anticoagulation Strategy

The American College of Chest Physicians strongly recommends direct oral anticoagulants (DOACs) over vitamin K antagonists as first-line therapy for the initial 3-month treatment phase of acute DVT treatment, specifically apixaban, dabigatran, edoxaban, or rivaroxaban 1
Anticoagulation should be started immediately upon DVT diagnosis without waiting for confirmatory testing if clinical suspicion is high 2, 3
DOACs are strongly preferred over warfarin due to similar efficacy with lower bleeding risk, no monitoring requirements, and greater convenience 1
The four approved DOACs (apixaban, dabigatran, edoxaban, rivaroxaban) are all acceptable first-line options 1

If DOACs are contraindicated or unavailable, start parenteral anticoagulation (LMWH or fondaparinux preferred over UFH) simultaneously with warfarin on day 1 4, 2, 3
Continue parenteral therapy for minimum 5 days AND until INR ≥2.0 for at least 24 hours 4, 2, 3
Target INR range: 2.0-3.0 (target 2.5) 4, 2, 3

For provoked DVT, treat for exactly 3 months, then stop if DVT occurred with a major transient risk factor (e.g., surgery, trauma) 1
For unprovoked DVT, complete initial 3-month treatment phase, then offer extended-phase anticoagulation (no scheduled stop date) with a DOAC 1

For cancer-associated DVT, use oral Factor Xa inhibitors (apixaban, edoxaban, or rivaroxaban) over LMWH as first-line therapy 1
For antiphospholipid syndrome, use adjusted-dose warfarin (target INR 2.5) over DOACs during the treatment phase 1
For isolated distal DVT without severe symptoms or extension risk factors, serial imaging for 2 weeks is suggested over immediate anticoagulation 4, 2, 3

Outpatient home-based treatment is strongly recommended over hospitalization for patients with adequate home circumstances 1, 4, 2, 3

Do NOT use IVC filters in patients who can receive anticoagulation 5
Anticoagulation alone is preferred over catheter-directed thrombolysis for most DVT patients 4